Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow CARGO Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for CARGO Therapeutics, Inc.

CRGX

CARGO Therapeutics, Inc.

About CARGO Therapeutics, Inc.

CARGO Therapeutics, Inc. is a clinical-stage biotechnology company developing next-generation CAR T-cell therapies for cancer, focusing on B-cell malignancies. Its core products include CRG-023, a tri-specific autologous CAR T therapy targeting CD19, CD20, and CD22 antigens, and a universal allogeneic vector platform designed to overcome immune rejection and manufacturing challenges. CARGO aims to enhance durability, safety, and patient access through innovative cell engineering and manufacturing technologies.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from CARGO Therapeutics, Inc.

1
1
CARGO Therapeutics, Inc. CARGO Therapeutics Reports $49.9 Million Net Loss in Q2 2025, Enters Merger Agreement with Concentra Biosciences

Via official filing (AI summary) | 11 months ago | 0 comments

2
1
CARGO Therapeutics, Inc. CARGO Therapeutics Reports $84.5 Million Net Loss and Major Restructuring Efforts

Via official filing (AI summary) | about 1 year ago | 0 comments

3
1
CARGO Therapeutics, Inc. CARGO Therapeutics Reports $167.5 Million Net Loss for 2024, Discontinues FIRCE-1 Study

Via official filing (AI summary) | over 1 year ago | 0 comments

4
1
CARGO Therapeutics, Inc. Cargo Therapeutics Reports Significant Financial Developments, Including Decrease in Cash Reserves and Increased Losses

Via official filing (AI summary) | over 1 year ago | 0 comments